These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

216 related items for PubMed ID: 16219898

  • 1. Natalizumab for the treatment of multiple sclerosis and Crohn's disease.
    Keeley KA, Rivey MP, Allington DR.
    Ann Pharmacother; 2005 Nov; 39(11):1833-43. PubMed ID: 16219898
    [Abstract] [Full Text] [Related]

  • 2. Natalizumab: pharmacology, clinical efficacy and safety in the treatment of patients with Crohn's disease.
    Ko HH, Bressler B.
    Expert Rev Gastroenterol Hepatol; 2007 Oct; 1(1):29-39. PubMed ID: 19072431
    [Abstract] [Full Text] [Related]

  • 3. Clinical evaluation of natalizumab for formulary consideration.
    Bivins A, Hou K, Ayesu N, Ellsworth B, Montenegro S, Tu X, Boyle C, Dowling T, Shaya FT.
    Expert Opin Biol Ther; 2010 Aug; 10(8):1279-87. PubMed ID: 20626228
    [Abstract] [Full Text] [Related]

  • 4. Natalizumab for induction of remission in Crohn's disease.
    Macdonald JK, McDonald JW.
    Cochrane Database Syst Rev; 2006 Jul 19; (3):CD006097. PubMed ID: 16856112
    [Abstract] [Full Text] [Related]

  • 5. The role of natalizumab in the treatment of multiple sclerosis.
    Coyle PK.
    Am J Manag Care; 2010 Jun 19; 16(6 Suppl):S164-70. PubMed ID: 20615052
    [Abstract] [Full Text] [Related]

  • 6. Multiple sclerosis, natalizumab therapy, and progressive multifocal leukoencephalopathy.
    Bartt RE.
    Curr Opin Neurol; 2006 Aug 19; 19(4):341-9. PubMed ID: 16914971
    [Abstract] [Full Text] [Related]

  • 7. Natalizumab for induction of remission in Crohn's disease.
    MacDonald JK, McDonald JW.
    Cochrane Database Syst Rev; 2007 Jan 24; (1):CD006097. PubMed ID: 17253580
    [Abstract] [Full Text] [Related]

  • 8. Assessment: the use of natalizumab (Tysabri) for the treatment of multiple sclerosis (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
    Goodin DS, Cohen BA, O'Connor P, Kappos L, Stevens JC, Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
    Neurology; 2008 Sep 02; 71(10):766-73. PubMed ID: 18765653
    [Abstract] [Full Text] [Related]

  • 9. Natalizumab: new drug. Multiple sclerosis: risky market approval.
    Prescrire Int; 2008 Feb 02; 17(93):7-10. PubMed ID: 18354844
    [Abstract] [Full Text] [Related]

  • 10. [Natalizumab in multiple sclerosis: unclear patient benefits].
    Schipper JP.
    Ned Tijdschr Geneeskd; 2007 Apr 14; 151(15):852-5. PubMed ID: 17472115
    [Abstract] [Full Text] [Related]

  • 11. Natalizumab: targeting alpha4-integrins in multiple sclerosis.
    Engelhardt B, Kappos L.
    Neurodegener Dis; 2008 Apr 14; 5(1):16-22. PubMed ID: 18075270
    [Abstract] [Full Text] [Related]

  • 12. [Natalizumab in the treatment of multiple sclerosis].
    Horga A, Horga de la Parte JF.
    Rev Neurol; 2008 Apr 14; 45(5):293-303. PubMed ID: 17876741
    [Abstract] [Full Text] [Related]

  • 13. Recommendations for the selection, treatment, and management of patients utilizing natalizumab therapy for multiple sclerosis.
    Foley J.
    Am J Manag Care; 2010 Jun 14; 16(6 Suppl):S178-83. PubMed ID: 20615054
    [Abstract] [Full Text] [Related]

  • 14. Natalizumab: alpha 4-integrin antagonist selective adhesion molecule inhibitors for MS.
    Rudick RA, Sandrock A.
    Expert Rev Neurother; 2004 Jul 14; 4(4):571-80. PubMed ID: 15853576
    [Abstract] [Full Text] [Related]

  • 15. [Selective adhesion molecule inhibitors. Natalizumab in multiple sclerosis and Crohn's disease].
    Hennemann A.
    Med Monatsschr Pharm; 2003 May 14; 26(5):146-8. PubMed ID: 12784500
    [No Abstract] [Full Text] [Related]

  • 16. Natalizumab. Elan/Biogen.
    Elices MJ.
    Curr Opin Investig Drugs; 2003 Nov 14; 4(11):1354-62. PubMed ID: 14758775
    [Abstract] [Full Text] [Related]

  • 17. [Efficacy and safety of natalizumab for multiple sclerosis and Crohn's disease: a meta analysis].
    Li YY, Li YP, Sun X, Wang L, Wen J, Cheng L.
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2010 Oct 14; 32(5):533-42. PubMed ID: 21050557
    [Abstract] [Full Text] [Related]

  • 18. Natalizumab for the treatment of Crohn's disease.
    Bickston SJ, Muniyappa K.
    Expert Rev Clin Immunol; 2010 Jul 14; 6(4):513-9. PubMed ID: 20594122
    [Abstract] [Full Text] [Related]

  • 19. Natalizumab (Tysabri) treatment for relapsing multiple sclerosis.
    Johnson KP.
    Neurologist; 2007 Jul 14; 13(4):182-7. PubMed ID: 17622909
    [Abstract] [Full Text] [Related]

  • 20. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial.
    Targan SR, Feagan BG, Fedorak RN, Lashner BA, Panaccione R, Present DH, Spehlmann ME, Rutgeerts PJ, Tulassay Z, Volfova M, Wolf DC, Hernandez C, Bornstein J, Sandborn WJ, International Efficacy of Natalizumab in Crohn's Disease Response and Remission (ENCORE) Trial Group.
    Gastroenterology; 2007 May 14; 132(5):1672-83. PubMed ID: 17484865
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.